| ||||||||||||||
|
|
|||||||||||||
Department of Anesthesiology and Pain Management, University of Texas, Southwestern Medical Center at Dallas, Dallas, Texas
Address correspondence and reprint requests to Dr. Girish P. Joshi, Department of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75235-9068. Address e-mail to girish.joshi @email.swmed.edu.
| Abstract |
|---|
|
|
|---|
Implications: In this study, we showed that the incidence of postoperative nausea and vomiting and the need for antiemetics do not increase with the use of neostigmine and glycopyrrolate for reversal of residual muscle paralysis.
| Introduction |
|---|
|
|
|---|
Perhaps the use of neostigmine to antagonize nondepolarizing muscle relaxants increases the incidence of PONV (46). In contrast, a study reported that reversal of neuromuscular blockade with a combination of neostigmine and glycopyrrolate had no effect on the incidence or severity of PONV on inpatients undergoing abdominal hysterectomy (7). However, the incidence of PONV after ambulatory surgery is more frequent than that after inpatient surgery (8). The effects of a neostigmine-glycopyrrolate combination on the incidence of PONV in patients undergoing ambulatory surgery have not been determined.
We designed the present study to evaluate the effects of a neostigmine-glycopyrrolate combination on the incidence of PONV and the need for antiemetic medication in patients undergoing ambulatory surgery.
| Methods |
|---|
|
|
|---|
After premedication with midazolam 2 mg IV, general anesthesia was induced with fentanyl 1 µg/kg IV and propofol 22.5 mg/kg IV. Using a computer-generated random number sequence, patients were randomly assigned to receive either mivacurium or rocuronium to achieve muscle relaxation. Tracheal intubation was facilitated using either mivacurium 0.25 mg/kg IV administered in divided doses0.15 mg/kg IV followed 30 s later by 0.1 mg/kg (n = 50)or rocuronium 0.6 mg/kg IV (n = 50). Mivacurium 0.25 mg/kg administered in divided doses provides good to excellent intubation conditions with hemodynamic stability after a midazolam, fentanyl, and propofol induction sequence (9). Anesthesia was maintained with isoflurane (0.5%1.5% end-tidal concentrations) in combination with nitrous oxide 60% in oxygen. The concentrations of isoflurane were adjusted according to standard clinical practice (i.e., to maintain hemodynamic variables within 20% of the baseline values). Supplemental doses of fentanyl 2550 µg IV were administered if the volatile anesthetic failed to maintain adequate hemodynamic stability. All patients' lungs were mechanically ventilated to maintain end-tidal carbon dioxide at 3236 mm Hg. Bolus doses of mivacurium 24 mg or rocuronium 510 mg were administered to maintain one or two twitches of the train-of-four stimulation of the ulnar nerve at the wrist. Residual neuromuscular blockade was reversed with neostigmine 2.5 mg IV and glycopyrrolate 0.5 mg IV only if deemed clinically necessary (i.e., fade on train-of-four stimulation, inadequate tidal volume, reduced hand grip, or inability to maintain head lift).
In the postoperative period, incidence of nausea, vomiting, and pain and the need for treatment were recorded by a blinded observer in the postanesthesia care unit (PACU) and the step-down (phase II) unit. Rescue medications for nausea and/or vomiting were administered if it lasted >15 min or if, at any time, a patient requested them. The choice of rescue antiemetic was left to the discretion of the attending anesthesiologist. If necessary, patients received fentanyl 2550 µg IV or oral analgesic medications in the PACU or step-down unit, respectively. The time from end of surgery to extubation and the time to "fit for discharge" from the PACU and the hospital were noted. Patients were contacted by telephone 24 h after surgery regarding the incidence of nausea, vomiting, and pain and the need for medications after discharge. In addition, the patients rated their overall satisfaction with anesthesia using a 5-point scale ranging from completely satisfied to completely dissatisfied.
We compared patients who received neostigmine at the end of surgery with those who did not. Power analysis performed using a predicted incidence of postoperative nausea of 30%40% (14) suggested that a sample size of 40 patients in each group should be adequate to achieve a power of 0.8 and an
of 0.05. Continuous variables (e.g., demographic data, duration of anesthesia, anesthetic requirements) were analyzed by using Student's t-tests. Nonparametric variables were analyzed by using the Mann-Whitney U-test or
2 test with Yates' continuity correction, as appropriate. A P value of <0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
|
|
| Discussion |
|---|
|
|
|---|
Interestingly, Boeke et al. (10) found that the administration of smaller doses of neostigmine 1.5 mg in combination with atropine 0.5 mg in patients undergoing outpatient peripheral surgery actually reduced the need for antiemetic medications. However, these investigators did not observe any difference in the frequency of nausea or vomiting between the patients who received the reversal drugs and those who did not. The use of atropine with neostigmine (instead of glycopyrrolate) may have been responsible for the decreased need for antiemetics. Unlike glycopyrrolate, atropine crosses the blood-brain barrier and is reported to have some antiemetic effect (11). Janhunen and Tammisto (12) reported a decreased incidence of PONV when neostigmine and atropine were administered to reverse residual neuromuscular blockade. However, current standard practice is to use combinations of neostigmine and glycopyrrolate (rather than neostigmine and atropine) because of the similarities in their onset and duration of action.
In contrast to these findings, King et al. (4) reported a more frequent incidence of PONV with the administration of neostigmine 2.5 mg and atropine 1.2 mg in 38 patients (19 in each group) undergoing joint replacement surgery. Ding et al. (5) reported that the administration of neostigmine 2.5 mg and glycopyrrolate 0.5 mg after neuromuscular blockade with mivacurium increased the incidence of PONV in the PACU in women undergoing laparoscopic sterilization. However, they did not observe any difference in the incidence of PONV or the need for antiemetics after discharge from the PACU. Watcha et al. (6) reported that emesis occurred more often in the PACU in children receiving a neostigmine-glycopyrrolate combination, but not after receiving edrophonium-atropine. These investigators also found that the increased incidence of PONV due to reversal drugs was limited to the early recovery period. The conflicting results may be related to a number of factors, including the type of surgery (laparoscopic versus peripheral), the differences in the IV anesthetic drug (propofol versus thiopental), the dose of opioids, and the dose of neostigmine.
The incidence of PONV we observed is less frequent than that reported previously (46,13). This may be related to our use of propofol, compared with thiopental used by other investigators. A number of studies have reported a less frequent incidence of PONV with the use of propofol (14). In addition, differences in surgical procedures (i.e., peripheral surgical procedures versus abdominal procedure) may also have affected the incidence of PONV.
It is recommended that the dose of neostigmine should be matched with the degree of neuromuscular blockade (15). Furthermore, the routine administration of reversal drugs is controversial. In standard clinical practice, reversal drugs need not be administered in the presence of clinical recovery from neuromuscular blockade. Therefore, we evaluated the effects of neostigmine on the incidence of PONV in patients who would have received reversal drugs as a part of standard clinical practice compared with those who may not have received reversal drugs. This is in contrast to previous studies, in which reversal drugs were administered without considering the degree of neuromuscular blockade at the end of surgery.
Many practitioners avoid the use of reversal drugs because of their potential effects on the incidence of PONV. However, Kopman et al. (16) reported that even a minor degree of residual paralysis (train-of-four ratio of 0.9) can cause various visual disturbances, decreased grip strength, inability to maintain incisor teeth apposition, inability to sit up without assistance, severe facial weakness (including inability to maintain an airtight seal around drinking straw with the lips), and overall weakness and tiredness. These symptoms may be present despite the signs of clinical recovery from neuromuscular blockade. In addition to being distressing to the patients, these symptoms can prolong the time to home-readiness and delay discharge. Because of these potential complications, particularly in an outpatient setting, it is necessary that reversal drugs be used (in appropriate doses) frequently.
The choice of muscle relaxant is an important factor in the avoidance of residual neuromuscular blockade (13,15). Because short-acting nondepolarizing neuromuscular blocking drugs such as mivacurium facilitate rapid spontaneous recovery, it is not surprising that the need for reversal drugs after the use of mivacurium was significantly decreased compared with that after the use of rocuronium. Pino et al. (9) reported a more predictable recovery profile with the use of mivacurium compared with the use of rocuronium. Therefore, using shorter acting muscle relaxants may be more advantageous in patients undergoing ambulatory surgery.
In conclusion, in this study we demonstrated that, compared with rocuronium, the use of mivacurium decreased the need for reversal drugs. However, reversal of residual neuromuscular blockade with neostigmine 2.5 mg and glycopyrrolate 0.5 mg does not increase the incidence of PONV or the need for rescue antiemetic medications in patients undergoing ambulatory surgery.
| Acknowledgments |
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
A. Srivastava and J. M. Hunter Reversal of neuromuscular block Br. J. Anaesth., July 1, 2009; 103(1): 115 - 129. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Tait, C. Burke, T. Voepel-Lewis, D. Chiravuri, D. Wagner, and S. Malviya Glycopyrrolate Does Not Reduce the Incidence of Perioperative Adverse Events in Children with Upper Respiratory Tract Infections Anesth. Analg., February 1, 2007; 104(2): 265 - 270. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Tran, T. J. Ganley, L. Wells, A. Ganesh, K. I. Minger, and G. Cucchiaro Intraarticular Bupivacaine-Clonidine-Morphine Versus Femoral-Sciatic Nerve Block in Pediatric Patients Undergoing Anterior Cruciate Ligament Reconstruction Anesth. Analg., November 1, 2005; 101(5): 1304 - 1310. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-R. Cheng, D. I. Sessler, and C. C. Apfel Does Neostigmine Administration Produce a Clinically Important Increase in Postoperative Nausea and Vomiting? Anesth. Analg., November 1, 2005; 101(5): 1349 - 1355. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|